Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Allied Physicians, Inc

Neither a doctor nor a teaching hospital

Research payments

$92,099

50 payments

Through program year 2025, Allied Physicians, Inc is reported as receiving $92,099 in research payments, across 50 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $3,700 2
2024 Research $49,482 42
2023 Research $11,358 1
2022 Research $15,203 2
2019 Research $12,356 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ipsen Innovation $38,523 35 payments
  2. Celgene Corporation $15,346 2 payments
  3. Ucb SA $12,700 3 payments
  4. Eisai Inc. $12,356 3 payments
  5. Ipsen Pharma SAS $6,971 6 payments
  6. Alexion Pharmaceuticals, Inc. $6,203 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $38,438 34 payments
  2. A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) $15,346 2 payments
  3. A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy $12,356 3 payments
  4. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures $10,850 2 payments
  5. A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity $6,971 6 payments
  6. A Phase III, Open label, Extension Trial of ECU NMO 301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) $6,203 1 payment
  7. An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures $1,850 1 payment
  8. Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $85 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record